Because helix-loop-helix (HLH) transcription factors appear to play an important role in mesodermal development, we have investigated the potential role of these factors in cardiac gene expression. HLH proteins interact with DNA at consensus "E-box" sites and may be tissue specific or more widely expressed. We have examined cardiac cells for expression and regulation of widely expressed factors Panl/Pan2 and the inhibitor of differentiation (Id) by RNase protection analysis. 
T he factors that are involved in determination of cardiac muscle are unknown. In the vertebrate embryo, cardiac muscle derives from the splanchnic mesoderm, part of the lateral mesoderm. Several members of the basic helix-loop-helix (HLH) family of transcription factors appear to play a pivotal role in mesodermal development, including MyoD, MyoD family members,' and Twist. 2 The MyoD family is specifically expressed in skeletal muscle lineages, whereas Twist appears to be expressed in the lateral mesoderm. The mesodermal origin of cardiac cells and overlapping expression of many genes in cardiac and skeletal muscle suggest that basic HLH proteins may play a role in cardiac gene expression.
Basic HLH proteins affect gene expression by binding to a consensus DNA binding site, the "E-box." The DNA binding activity of tissue-restricted HLH proteins such as MyoD may be modulated by their interaction via the HLH domain with more widely expressed HLH family members. Such family members include splice variants of the E2 gene, two of which are E12 and E47.3 E12 and E47 form heterodimers with tissue-specific basic HLH proteins, such as the MyoD family, increasing their DNA binding affinity. Rat homologues of the human E12/E47 genes, Pan2/Panl, have also been cloned. 4 Cotransfection of E47 or Panl/Pan2 expression vectors with E-box-containing promoter response elements results in an upregulation of promoter activity. [4] [5] [6] Another family of widely expressed HLH factors negatively modulates tissue-specific expression. One of these is the inhibitor of differentiation (Id).7 Id lacks the basic DNA binding domain of other HLH family members, resembling dominant negative mutants of MyoD. Id mRNA levels are high in skeletal myoblasts grown in high serum and are downregulated in response to serum withdrawal, as myotube formation occurs and skeletal muscle genes are activated. Id cotransfections adversely affect tissue-specific activity of several E-box-dependent promoter elements.7-10 In this way, endogenous levels of E12/E47 and Id may create an environment that is permissive for MyoD or analogous HLH proteins.
We have been interested in investigating the possible role of HLH proteins in cardiac development and in cardiac gene expression (for discussion, see Reference 11) . In the present study, we examine the role of Id and Panl/Pan2 in cardiac gene expression. Our generously provided his pCKCATE4 construct,'8 from which the muscle creatine kinase (MCK) 302-bp enhancer was excised with BamHI and subcloned into the luciferase expression vector pT109.'9 The py-AchRLuc plasmid is a 720-bp fragment of the y-acetylcholine receptor subunit (-y-AchR) promoter subcloned into the luciferase vector pXP.l as previously described. 20 The parent plasmid for atrial natriuretic factor (ANF)-and myosin light chain-2 (MLC2)-luciferase promoter expression vectors is pS-VOALA5.15,21 The MLC2 deletion construct pMLC5OLuc contains nucleotides -30 to +20 of the MLC2 promoter region cloned into the multiple cloning site of luciferase vector pXP.l. The cytomegalovirus (CMV)-j3-galactosidase expression vector used for normalization of transfection efficiency was pON249,22 and the control Rous sarcoma virus (RSV)-luciferase plasmid has been described. 23 Transient transfection assays were performed by a modification of the calcium phosphate precipitation method24 as previously described.'S Neonatal ventricular myocytes were plated at a density of 2.7x 106 cells per 60-mm dish and incubated in low-serum medium for 48 hours after washing the calcium phosphate precipitate. C3H1OT1/2 cells were transfected in high serum at 80% confluence in 60-mm dishes and were also incubated for 48 hours in low-serum medium after washing the calcium phosphate precipitate. Skeletal muscle cell lines Sol8 and C2C12 were transfected in high serum at 80% confluence, were placed in low-serum medium after transfection, and were allowed to fuse before harvesting (usually after 48 to 72 hours in fusion medium). Cells were harvested by adding a 0.5% Triton lysis buffer as previously described.28 Luciferase and253-galactosidase activities were assayed as previously described,15 and protein concentrations were determined by protein assay (BioRad Laboratories, Richmond, Calif).
Results

Pan] and Pan2 Isoform mRNAs Are Expressed in Cardiac Muscle
Previously, Northern blot analysis of cardiac RNA has shown a 3.0-kb mRNA species that hybridizes to probes for Panl or Pan2. 4 However, the shared sequences of these isoforms do not allow a conclusion to be reached from these data as to which isoform is expressed. Panl and Pan2 are two of several isoforms of the E2A gene. Because there appear to be functional differences between E2A isoforms that may play a role in tissue-specific expression,326 we examined which of these isoforms is expressed in cardiac muscle cells by RNase protection analysis. Probes from the HLH regions, specific for Panl or Pan2 mRNAs, were used to analyze RNAs from AR42J cells (the parent rat pancreatic cell line), RMo cells (a rat muscle cell line), rat primary neonatal ventricular myocytes, and adult rat ventricle and atrium. Our results with Panl-and Pan2-specific probes were identical and indicated that both isoforms are expressed in all cell types examined. Levels of Panl and Pan2 mRNAs in primary neonatal ventricular cells were comparable to those seen in parental AR42J cells and in RMo myoblasts and myotubes. Levels of Panl and Pan2 mRNAs in RNA from whole ventricle or atria were comparatively lower (data not shown). 26 In addition, Panl and Pan2 expression vectors can activate an oligomerized E-box-containing enhancer from the chymotrypsin gene, which is contained within the reporter plasmid pCHY7Luc. 4 Therefore, activation of a control region by Panl or Pan2 in a transient transfection assay could implicate a potential E-box-dependent pathway. We have examined the response of skeletal and cardiac promoters to coexpression of either Panl or Pan2 in both 10T1/2 cells and primary cardiac cells. Data from the 10T1/2 transfections are shown in Table  4 . As expected from results of previous investigators, both pCMVPanl and pCMVPan2 activated pCHY7Luc and pMCKLuc approximately fourfold. In addition, py-AchRLuc was also activated from 6-fold to 15- demonstrating that the neonatal ventricular cell environment is permissive for MyoD. This observation extends recent results in transgenic mice, where ectopic expression of MyoD resulted in the expression of skeletal muscle markers in embryonic hearts.39 As the transgenic mice died before birth, the effect of expression in the neonatal heart could not be examined. In addition, we have tried to examine more closely the effect of MyoD expression on several genes normally expressed in cardiac cells. MyoD expression could affect cardiac expression by binding to potential recognition sites or could theoretically downregulate expression by competing for a partner required for activation. Recently, low levels of MyoD mRNA have been reported in adult Xenopus heart,40 raising the possibility of low levels of MyoD expression in the mammalian heart.
Although MyoD activated an E-box-containing MCK enhancer in C3H1OT1/2 cells, consistent with results of previous investigators,5 MyoD did not activate the same enhancer in primary neonatal ventricular cells. This may be a reflection of the fact that the MCK enhancer is expressed in cardiac cells and that MyoD is unable to increase transcriptional levels further, perhaps because of the lack of E-box accessibility or the inability of MyoD to activate over and above endogenous transcription factors. Similarly, although MyoD was capable of activating cardiac-specific promoters of ANF and MLC2 genes in 1OT1/2 cells, it did not affect the activity of these two promoters in cardiac muscle cells. MyoD has previously been shown to activate promoters other than skeletal muscle promoters in transient cotransfection assays.1.33 This activation may be direct or indirect. In addition, the MLC2 gene is expressed in slow skeletal muscle,32 although it is not known whether the 2700-bp promoter is sufficient to confer skeletal muscle-specific expression.
Cotransfection of an Id expression vector with MCK, ANF, and MLC2 promoter element-reporter constructs did not appear to affect their expression. However, the Id expression vector can be effective in primary neonatal ventricular cells, as indicated by its ability to counteract MyoD activation of the y-AchR promoter. Inability of Id to downregulate the three cardiac promoters may indicate that their activity in neonatal ventricular myocytes is largely independent of an E-box-mediated pathway, which can be affected by Id. Consistent with this, activation of the MLC2 promoter has been shown to be mediated by an E-boxindependent pathway. 34 Recently, other investigators have demonstrated that the Hfla site that mediates cardiac-specific activity of the MLC2 promoter is capable of recognizing an E-box-binding complex, which binds to the a-myosin heavy chain promoter. 41 This observation has led to the proposal that the Hfla site is a modified E-box. Our results indicate that, if Hfla is an E-box-binding protein, it is one that cannot be inhibited by Id. Both MLC2 and ANF genes are upregulated in response to PE stimulation,15,2' and our results indicate that Id mRNA levels also increase with PE stimulation. These observations are consistent with the inability of Id cotransfection to downregulate activity of these two cardiac promoters. Insensitivity of the MCK enhancer activity to ectopic Id expression in cardiac cells is contrary to what has been previously described for activity of this enhancer in skeletal muscle cells.7 From this result, it would seem that the E-box sites within the MCK enhancer may be less important in the cardiac cell context relative to other potential DNA binding sites within the enhancer. In this way, the MCK enhancer differs from the a-cardiac actin promoter element, which appears to be E-box dependent in both skeletal and cardiac muscle contexts.37i42
Despite the ability of expression vectors for Panl and Pan2 to activate E-box target reporter genes in C3H1OT1/2 cells, consistent with results of previous investigators,4 ' 26 no activation by these expression vectors of E-box target promoters was observed in cardiac cells. In fact, a negative effect was observed for pCHY7Luc and pT109. This observation suggests that Panl and Pan2 have the potential to act as negative regulators of transcription and that the cardiac context may enhance this potential on specific promoters. In support of this idea, a specific strong negative effect on MLC2700 promoter-reporter activity was observed on cotransfection with Panl or Pan2 expression vectors. The specificity of this effect was demonstrated by the lack of effect of cotransfection of Panl or Pan2 expression vectors on the cardiac specific expression of the MCK-luciferase and ANF-luciferase constructs. The ANF-luciferase promoters were cloned into the same vector as the MLC2-luciferase promoter constructs, indicating that the negative effect was not due to vector sequences. The fold decrease in MLC2700 promoter activity increased with increasing ratios of pCMVPanl or pCMVPan2 to pMLC2700Luc. Mapping of the site of action for Panl and Pan2 within the MLC2 promoter by cotransfections with successive deletions of the MLC2700 promoter35 indicated that the sites of action are throughout the 2700-bp promoter region. Point mutations within a 250-bp fragment of the MLC2 promoter within E-box or Hflb/ MEF2 sites34 had no effect on the negative regulation by Panl/Pan2, indicating that their site of action must be other than these sites. Our results with Panl and Pan2 and the MLC250 promoter mutants indicate that the negative effect of Pan on this promoter fragment is not mediated through an E-box. The twofold negative effect within the 250 -bp fragment was mapped to 48 bp of the promoter region. The idea that Panl and Pan2 can act negatively as well as positively is further supported by the observation that expression of a ,3-galactosidase reporter gene, driven by a CMV enhancer, was consistently downregulated on cotransfection with Panl and Pan2 expression vectors in both C3HtOT1/2 embryonic fibroblast cells and in primary neonatal cardiac cells. This is the first report of a positively acting basic HLH protein also acting as a negative regulator. Members of other transcription factor families have been shown to be capable of both negative and positive gene regulation. With the leucine zipper Fos/Jun family, negative regulation can occur at AP1 sites or at non-AP1 sites, such as, for Jun, the E-box site. 43 
